Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg;~* For whom a parent/legal guardian has given written informed consent after the nature of the study has been explained.~Exclusion Criteria:~* History of any meningococcal B or C vaccine administration;~* prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens);~* Previous ascertained or suspected disease caused by N. meningitidis;~* History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;~* Significant acute or chronic infection within the previous 7 days or axillary temperature major or equal to38 degrees within the previous day;~* Antibiotics within 6 days prior to enrollment;~* Any serious chronic or progressive disease;~* Known or suspected impairment or alteration of the immune system;~* Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- B+R246 (Type: EXPERIMENTAL): Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.
- B246_R357 (Type: EXPERIMENTAL): Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.
- B+R234 (Type: EXPERIMENTAL): Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.
- R234 (Type: ACTIVE_COMPARATOR): Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).